The peptide-Au clusters inhibit EGFR exon 19 deletion mutant non-small cell lung cancer
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Ferroptosis and cancer prognosis · RNA modifications and cancer · Cancer Genomics and Diagnostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. Smoking-induced M2-TAMs, via circEML4 in EVs, promote the progression of NSCLC through ALKBH5-Regulated m6A modification of SOCS2 in NSCLC cells10.1002/advs.202300953 ↗
2. Afatinib resistance in non-small cell lung cancer volves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition10.1007/s11523-014-0344-7 ↗
3. Anti-cancer synergy of dichloroacetate and EGFR tyrosine kinase inhibitors in NSCLC cell lines10.1016/j.ejphar.2016.08.004 ↗
4. TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway10.1124/jpet.114.215418 ↗
5. Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells10.18632/oncotarget.2017 ↗
6. Cell behavior of non-small cell lung cancer is at EGFR and MicroRNAs hands10.3390/ijms222212496 ↗
7. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer10.1200/JCO.2009.26.2543 ↗
8. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics10.1016/j.ccr.2014.02.025 ↗
9. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
10. Genomic alterations in lung adenocarcinoma10.1016/S1470-2045(15)00077-7 ↗
11. Cancer statistics, 201410.3322/caac.21208 ↗
12. Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)10.1007/s11523-013-0258-9 ↗
13. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer10.1016/S0960-894X(01)00344-4 ↗
14. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy
15. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
16. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models10.1038/onc.2008.109 ↗
17. Afatinib: first global approval10.1007/s40265-013-0111-6 ↗
18. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor10.1158/1535-7163.MCT-07-2232 ↗
19. Tyrosine kinase inhibitors. 20. Optimization of substituted quinazoline and pyrido[3,4-d]pyrimidine derivatives as orally active, irreversible inhibitors of the epidermalgrowth factor receptor family10.1021/acs.jmedchem.6b00883 ↗
20. Olmutinib: first global approval10.1007/s40265-016-0606-z ↗
21. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer10.1056/NEJMoa1411817 ↗
22. Rociletinib in EGFR-mutated non-small-cell lung cancer10.1056/NEJMoa1413654 ↗
23. Resistance mechanisms to targeted therapies in ROS1(+) and ALK(+) non-small cell lung cancer10.1158/1078-0432.CCR-17-2452 ↗
24. Acquired resistance is oncogene and drug agnostic10.1016/j.ccell.2019.09.011 ↗
25. The efficacy of synchronous combination of chemotherapy and EGFR TKIs for the first-line treatment of NSCLC: a systematic analysis10.1371/journal.pone.0135829 ↗
26. Atomically precise gold nanoclusters as new model catalysts10.1021/ar300213z ↗
27. Metal nanoclusters: novel probes for diagnostic and therapeutic applications10.1039/C5CS00607D ↗
28. Engineering gold-based radiosensitizers for cancer radiotherapy10.1039/C7MH00451F ↗
29. Computational design of peptide-Au cluster probe for sensitive detection of α(IIb)β3 integrin10.1039/C5NR09175F ↗
30. Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers
31. Peptide-Au cluster probe: precisely detecting epidermal growth factor receptor of three tumor cell lines at a single-cell level10.1021/acsomega.6b00390 ↗
32. Small peptide ligands for targeting EGFR in triple negative breast cancer cells10.1038/s41598-019-38574-y ↗
33. Controlled growth of molecularly pure Au25(SR)18 and Au38 (SR)24 nanoclusters from the same polydispersed crude product10.1007/s11426-012-4669-8 ↗
34. Clathrin-dependent entry and vesicle-mediated exocytosis define insulin transcytosis across microvascular endothelial cells10.1091/mbc.E14-08-1307 ↗
35. Enhancement of airway gene transfer by DNA nanoparticles using a pH-responsive block copolymer of polyethylene glycol and poly-L-lysine10.1016/j.biomaterials.2011.11.080 ↗